Aspreva Pharmaceuticals
Manufacturing · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4464 Markham St Unit 1203, Victoria, Bri...Phone Number
(908) 542-1268Website
www.aspreva.comRevenue
$23 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Aspreva Pharmaceuticals
Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercialising evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV".Explore more
Aspreva Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aspreva Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Aspreva Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Aspreva Pharmaceuticals
Click to see if Aspreva Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Aspreva Pharmaceuticals has new funding data
Check if Aspreva Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Aspreva Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Aspreva Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Aspreva Pharmaceuticals recently announced quarterly report
Recommended Actions
Find VP level buyers at Aspreva Pharmaceuticals
Find more new buyers
Compare Similar Companies to Aspreva Pharmaceuticals
Compare insights from companies similar to Aspreva Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aspreva Pharmaceuticals
$23M
51-200
Private
-
2001
DO
Darcy O'GradyGlobal Vice President, Human Resources
Company Profile Activity
Activity Insights
Aspreva Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aspreva Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aspreva Pharmaceuticals.
Aspreva Pharmaceuticals News & Media
Kane Biotech Appoints Pharmaceutical Executive Rashieda Gluck to Board of Directors
WINNIPEG, Manitoba, May 22, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce it has appointed Rashieda (Rivka) Gluck to the Corporation’s Board of Directors. With over 20 years of experience in the global pharmaceutical, biotechnology, and life science industries, Ms. Gluck’s career has spanned all levels and functions in clinical development. As an executive, her focus has been on leading the strategic planning a
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Aspreva Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercialising evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV".... Read More
